News
AMPH
19.00
-20.93%
-5.03
AMPHASTAR PHARMACEUTICALS, INC <AMPH.O>: PIPER SANDLER CUTS TARGET PRICE TO $21 FROM $25
Reuters · 5h ago
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narrative Despite Stable Revenue
Simply Wall St · 2d ago
Amphastar Balances Margin Pain With Pipeline Gains
TipRanks · 2d ago
Amphastar downgraded to Hold from Buy at Needham
TipRanks · 2d ago
Amphastar cut to Hold at Needham after ‘disappointing’ results
TipRanks · 2d ago
Amphastar reports Q1 EPS 42c, consensus 71c
TipRanks · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Benzinga · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2d ago
Amphastar Pharmaceuticals Cut to Hold From Buy by Needham
Dow Jones · 2d ago
Needham downgrades Amphastar Pharmaceuticals (AMPH) to a Hold
TipRanks · 2d ago
Needham Downgrades Amphastar Pharma to Hold
Benzinga · 2d ago
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 2d ago
Why Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Squeeze Despite Flat Q1 2026 Sales
Simply Wall St · 3d ago
Amphastar (AMPH) Q1 2026 Earnings Transcript
The Motley Fool · 3d ago
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
NASDAQ · 3d ago
Amphastar Q1 revenue and adjusted EPS miss estimates
Reuters · 3d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 3d ago
Amphastar Pharmaceuticals to present at Bank of America Health Care Conference webcast
PUBT · 4d ago
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.